Metahexamide | CAS#565-33-3 | anti-diabetic

MedKoo Cat#: 461619 | Name: Metahexamide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Metahexamide is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas.

Chemical Structure

Metahexamide

CAS#565-33-3

Theoretical Analysis

MedKoo Cat#: 461619

Name: Metahexamide

CAS#: 565-33-3

Chemical Formula: C11H20ClN5

Exact Mass: 257.1407

Molecular Weight: 257.76

Elemental Analysis: C, 51.26; H, 7.82; Cl, 13.75; N, 27.17

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Metahexamide; Euglycin; Melanex; S-1600; S 1600; S1600; U 9970; U-9970; U9970;

IUPAC/Chemical Name

6-chloro-N2,N2,N4,N4-tetraethyl-1,3,5-triazine-2,4-diamine

InChi Key

QHXDTLYEHWXDSO-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H20ClN5/c1-5-16(6-2)10-13-9(12)14-11(15-10)17(7-3)8-4/h5-8H2,1-4H3

SMILES Code

CCN(CC)C1=NC(Cl)=NC(N(CC)CC)=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 257.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: GALANSINO G, KANAMEISHI D, BERLINGER FG, FOA PP. Comparison of the mode of action of insulin and metahexamide. Metabolism. 1959 Jul 2;8(4 Pt 2):587-92. PubMed PMID: 13666406. 2: POLLEN RH, BARNES RH, TANNER DC, STIMSON WH, WILLIAMS RH. Treatment of diabetes with metahexamide. Diabetes. 1960 Jan-Feb;9:25-30. PubMed PMID: 14433864. 3: FORIST AA. Determination of metahexamide in human plasma. Ann N Y Acad Sci. 1959 Sep 25;82:496-501. PubMed PMID: 13823959. 4: MORGENSTERN LL, GARRETT ER. Determination of the half life of metahexamide in normal humans. Ann N Y Acad Sci. 1959 Sep 25;82:502-7. PubMed PMID: 14424136. 5: HABIB SA, KENNAWY MR, HASSANEIN M. Clinical experience with metahexamide in diabetes. J Egypt Med Assoc. 1960;43:14-25. PubMed PMID: 13710259. 6: CONCHA E, JIMENEZ E. [Therapeutic trials with metahexamide in diabetes]. Rev Med Chil. 1960 Dec;88:978-80. Spanish. PubMed PMID: 13694969. 7: WELLER C, MACAULAY A, LINDER M, TRACY JD. Clinical evaluation of metahexamide in the treatment of patients with diabetes mellitus. Metabolism. 1959 Jul 2;8(4 Pt 2):672-5. PubMed PMID: 13666415. 8: HAMWI GJ, SKILLMAN TG, KRUGER FA, ROUSH WH, FREEDY LR. Comparative pharmacology and clinical responses to metahexamide. Ann N Y Acad Sci. 1959 Sep 25;82:547-59. PubMed PMID: 14399399. 9: SUGAR SJ, THOMAS LJ. Clinical studies with metahexamide. Ann N Y Acad Sci. 1959 Sep 25;82:618-23. PubMed PMID: 13835564. 10: HAMWI GJ, SKILLMAN TG, FREEDY LR, ALEXANDER LA. Metabolic studies with metahexamide. Metabolism. 1959 Jul 2;8(4 Pt 2):631-43. PubMed PMID: 13666411. 11: HUSKISSON ID, JACKSON WP. Clinical trial of amino-methylbenzol-sulphonyl-cyclohexylurea (metahexamide) in diabetics after failure of tolbutamide. S Afr Med J. 1960 Jan 9;34:34-5. PubMed PMID: 14405589. 12: MACH B, FIELD RA, TAFT EB. Metahexamide jaundice: report of a case. N Engl J Med. 1959 Aug 27;261:438-40. PubMed PMID: 14419387. 13: FEDER IA, KAHN A. Clinical effectiveness and toxicity of metahexamide in treatment of diabetes mellitus. Metabolism. 1961 Mar;10:246-60. PubMed PMID: 13698510. 14: POLOSA P, MUGHINI L, DI SALVO C, LO TURCO F. [Our experience with the therapeutic use of metahexamide in diabetes mellitus]. Riforma Med. 1960 Nov 26;74:1380-5. Italian. PubMed PMID: 13736904. 15: ANDERSSEN N, SKJAEGGESTAD O. [Thrombocytopenia after treatment with metahexamide and chlorpropamide]. Tidsskr Nor Laegeforen. 1962 Aug 15;82:1037-8. Norwegian. PubMed PMID: 13861324. 16: WEST KM, JOHNSON PC. The comparative pharmacology of tolbutamide, carbutamide, chlorpropamide and metahexamide in man. Metabolism. 1959 Jul 2;8(4 Pt 2):596-605. PubMed PMID: 13666407. 17: OWEN JA Jr. A clinical comparison of tolbutamide, chlorpropamide and metahexamide in the treatment of diabetes. Metabolism. 1959 Jul 2;8(4 Pt 2):667-71. PubMed PMID: 13666414. 18: BAUER HG, SISLER EB, KUNG YT, McGAVACK TH. Some physiologic and therapeutic effects of the hypoglycemic agent, metahexamide, in group of 13 elderly diabetic men. Metabolism. 1959 Jul 2;8(4 Pt 2):644-54. PubMed PMID: 13666412. 19: IZZO JL. Comparison of relative hypoglycemic potencies and metabolic effects of metahexamide, chlorpropamide and tolbutamide in diabetes mellitus. Metabolism. 1959 Jul 2;8(4 Pt 2):621-30. PubMed PMID: 13666410. 20: GARATTINI S, JORI A, PALMA V, TESSARI L. On the hypoglycemizing effect of metahexamide. Experientia. 1959 Oct 15;15:384-5. PubMed PMID: 13826354.